JP2024505429A5 - - Google Patents

Info

Publication number
JP2024505429A5
JP2024505429A5 JP2023542915A JP2023542915A JP2024505429A5 JP 2024505429 A5 JP2024505429 A5 JP 2024505429A5 JP 2023542915 A JP2023542915 A JP 2023542915A JP 2023542915 A JP2023542915 A JP 2023542915A JP 2024505429 A5 JP2024505429 A5 JP 2024505429A5
Authority
JP
Japan
Prior art keywords
prodrug
composition
epinephrine
ester
pharmaceutically active
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023542915A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024505429A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/012633 external-priority patent/WO2022155544A1/en
Publication of JP2024505429A publication Critical patent/JP2024505429A/ja
Publication of JP2024505429A5 publication Critical patent/JP2024505429A5/ja
Pending legal-status Critical Current

Links

JP2023542915A 2021-01-15 2022-01-15 プロドラッグ組成物及び治療の方法 Pending JP2024505429A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163137881P 2021-01-15 2021-01-15
US63/137,881 2021-01-15
PCT/US2022/012633 WO2022155544A1 (en) 2021-01-15 2022-01-15 Prodrug compositions and methods of treatment

Publications (2)

Publication Number Publication Date
JP2024505429A JP2024505429A (ja) 2024-02-06
JP2024505429A5 true JP2024505429A5 (https=) 2025-01-24

Family

ID=80222567

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023542915A Pending JP2024505429A (ja) 2021-01-15 2022-01-15 プロドラッグ組成物及び治療の方法

Country Status (7)

Country Link
US (1) US20220233471A1 (https=)
EP (1) EP4277611A1 (https=)
JP (1) JP2024505429A (https=)
KR (1) KR20230134136A (https=)
CN (1) CN116940351A (https=)
CA (1) CA3208345A1 (https=)
WO (1) WO2022155544A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12440488B2 (en) 2020-12-01 2025-10-14 Reverspah Llc Methods and compositions for treating chronic obstructive pulmonary disease, asthma, pneumonia, bronchitis, cystic fibrosis, pulmonary edema, interstitial lung disease, sarcoidosis, idiopathic pulmonary fibrosis, acute respiratory distress syndrome, and pulmonary arterial hypertension
CN117695279A (zh) * 2023-11-28 2024-03-15 九华华源药业(桂林)有限公司 氯雷他定组合物及氯雷他定药物

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5429824A (en) 1992-12-15 1995-07-04 Eastman Kodak Company Use of tyloxapole as a nanoparticle stabilizer and dispersant
US5587143A (en) 1994-06-28 1996-12-24 Nanosystems L.L.C. Butylene oxide-ethylene oxide block copolymer surfactants as stabilizer coatings for nanoparticle compositions
US5569448A (en) 1995-01-24 1996-10-29 Nano Systems L.L.C. Sulfated nonionic block copolymer surfactants as stabilizer coatings for nanoparticle compositions
US5622938A (en) 1995-02-09 1997-04-22 Nano Systems L.L.C. Sugar base surfactant for nanocrystals
US5591456A (en) 1995-02-10 1997-01-07 Nanosystems L.L.C. Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer
US5580579A (en) 1995-02-15 1996-12-03 Nano Systems L.L.C. Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers
US5565188A (en) 1995-02-24 1996-10-15 Nanosystems L.L.C. Polyalkylene block copolymers as surface modifiers for nanoparticles
OA11529A (en) * 1998-03-16 2004-05-07 Inhale Therapeutic Syst Aerosolized active agent delivery.
US6153223A (en) 1998-06-05 2000-11-28 Watson Pharmaceuticals, Inc. Stabilized pharmaceutical compositions
US6428814B1 (en) 1999-10-08 2002-08-06 Elan Pharma International Ltd. Bioadhesive nanoparticulate compositions having cationic surface stabilizers
US7071186B2 (en) 1999-06-15 2006-07-04 Bristol-Myers Squibb Pharma Co. Substituted heterocycle fused gamma-carbolines
US6713471B1 (en) 1999-06-15 2004-03-30 Bristol-Myers Squibb Pharma Company Substituted heterocycle fused gamma-carbolines
ATE277048T1 (de) 1999-06-15 2004-10-15 Bristol Myers Squibb Pharma Co Substituierte hetercyclisch kondensierte gamma carboline
US20030051728A1 (en) * 2001-06-05 2003-03-20 Lloyd Peter M. Method and device for delivering a physiologically active compound
WO2003026631A1 (en) * 2001-05-24 2003-04-03 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
US8765167B2 (en) 2001-10-12 2014-07-01 Monosol Rx, Llc Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US7425292B2 (en) 2001-10-12 2008-09-16 Monosol Rx, Llc Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom
EP1471887B1 (en) 2002-02-04 2010-04-21 Elan Pharma International Ltd. Nanoparticulate compositions having lysozyme as a surface stabilizer
KR20040098023A (ko) 2002-03-26 2004-11-18 테바 파마슈티컬 인더스트리즈 리미티드 약물 미세입자
US7607436B2 (en) 2002-05-06 2009-10-27 The Research Foundation Of State University Of New York Methods, devices and formulations for targeted endobronchial therapy
SI1531794T1 (sl) * 2002-06-28 2017-12-29 Civitas Therapeteutics, Inc. Epinefrin za vdihavanje
WO2004002451A1 (fr) * 2002-06-28 2004-01-08 Fang Chen Suppositoire a liberation controlee utilise dans un canal secreteur de lait
GB0505420D0 (en) 2005-03-16 2005-04-20 Isogenica Ltd Stable ligand selection method
US20080078382A1 (en) 2006-09-20 2008-04-03 Lemahieu Edward Methods and Systems of Delivering Medication Via Inhalation
KR102107954B1 (ko) 2007-03-12 2020-05-07 인트라-셀룰라 써래피스, 인코퍼레이티드. 치환된 헤테로환 융합 감마-카르볼린 합성
CN101686939B (zh) * 2007-04-17 2013-03-27 巴克斯特国际公司 用于肺部投送的核酸微粒
AU2009223701B2 (en) 2008-03-12 2015-04-16 Intra-Cellular Therapies, Inc. Substituted heterocycle fused gamma-carbolines solid
EP3085231A1 (en) 2008-05-27 2016-10-26 Intra-Cellular Therapies, Inc. Method and compositions for sleep disorders and other disorders
ES2929343T3 (es) 2008-06-13 2022-11-28 Mannkind Corp Inhalador de polvo seco accionado por aspiración para la administración de fármacos
CA2796756A1 (en) 2010-04-22 2011-10-27 Intra-Cellular Therapies, Inc. Substituted pyrido(3',4':4,5)pyrrolo(1,2,3-de)quinoxalines for the treatment of central nervous system disorders
KR20140146192A (ko) 2012-04-14 2014-12-24 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
EA201590019A1 (ru) * 2012-07-05 2015-09-30 Арвен Айлак Санайи Ве Тиджарет А.С. Ингаляторы сухого порошка, содержащие носитель, отличный от лактозы
US20150250808A1 (en) * 2012-10-15 2015-09-10 Vojo P. Deretic Treatment of autophagy-based disorders and related pharmaceutical compositions, diagnostic and screening assays and kits
US9708322B2 (en) 2013-03-15 2017-07-18 Intra-Cellular Therapies, Inc. Substituted pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalines for inhibiting serotonin reuptake transporter activity
KR102373288B1 (ko) 2013-12-03 2022-03-10 인트라-셀룰라 써래피스, 인코퍼레이티드. 신규한 방법
CA2944755A1 (en) 2014-04-04 2015-10-08 Intra-Cellular Therapies, Inc. Organic compounds
US10077267B2 (en) 2014-04-04 2018-09-18 Intra-Cellular Therapies, Inc. Organic compounds
WO2015191554A1 (en) 2014-06-09 2015-12-17 Intra-Cellular Therapies, Inc. Compounds and methods of use to treat schizophrenia
US12433850B2 (en) * 2016-05-05 2025-10-07 Aquestive Therapeutics, Inc. Enhanced delivery epinephrine and prodrug compositions
CN110418639B (zh) * 2016-11-13 2023-06-02 艾奥诺医药有限公司 肾上腺素前药的舌下或口含给药制剂
KR20220126286A (ko) 2019-11-01 2022-09-15 어퀘스티브 테라퓨틱스, 아이엔씨. 전구약물 조성물 및 치료 방법

Similar Documents

Publication Publication Date Title
US11918655B2 (en) Intranasal epinephrine formulations and methods for the treatment of disease
JP6966981B2 (ja) ステロイドの抗痙攣活性
ES2309503T3 (es) Medicamento que comprende un agonista beta 2 de larga duracion, muy potente, en combinacion con otros ingredientes activos.
RU2018138195A (ru) Соединения 3,5-диамино-6-хлор-n-(n-(4- фенилбутил)карбамимидоил)пиразин-2-карбоксамида
JP2024505429A5 (https=)
IL172695A (en) Pharmaceutical composition comprising tiotropium bromide and salmetrol and use thereof for preparing a medicament for treating respiratory complaints
AU2007298814A1 (en) Galenic form for the trans-mucosal delivery of active ingredients
AU2021254650B2 (en) Intranasal epinephrine formulations and methods for the treatment of disease
JP2022512208A (ja) ベダキリンの組成物、それらを含む組み合わせ、それらを調製するための方法、それらを含む使用及び治療方法
JP2022526367A5 (https=)
JP2024528731A (ja) 眼癌転移を予防するためのイブジラスト
EP2296625A1 (en) Pharmaceutical formulation of ketorolac for intranasal administration
US20090098209A1 (en) Pharmaceutical compositions containing water-soluble derivatives of propofol and methods of administering same via pulmonary administration
KR100806541B1 (ko) 아세클로페낙을 함유하는 제어 방출성 제제
HK40121592A (en) Intranasal epinephrine formulations and methods for the treatment of disease
HK40092206A (zh) 鼻内肾上腺素制剂及治疗疾病的方法